writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 2, 2016

2016.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001:

1. Equity Bancshares, Inc., Wichita, Kansas, to acquire 100 percent of the voting shares of Community First Bancshares, Inc., and thereby indirectly acquire control of Community First Bank, both of Harrison, Arkansas.

B. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. *United Community Bancorp, Inc., Chatham, Illinois;* for prior approval to acquire Illini Corporation, Springfield, Illinois and thereby indirectly acquire Illini Bank, Springfield, Illinois and Farmers State Bank of Camp Point, Camp Point, Illinois.

Board of Governors of the Federal Reserve System, August 2, 2016.

Michele T. Fennell,

 $Assistant\ Secretary\ of\ the\ Board.$ [FR Doc. 2016–18691 Filed 8–5–16; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-16-0666]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to *omb@cdc.gov*. Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice.

Proposed Project

National Healthcare Safety Network (NHSN) (OMB No. 0920–0666, Exp. 12/31/2018)—Revision—National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The National Healthcare Safety Network (NHSN) is a system designed to accumulate, exchange, and integrate relevant information and resources among private and public stakeholders to support local and national efforts to protect patients and promote healthcare safety. Specifically, the data is used to determine the magnitude of various healthcare-associated adverse events and trends in the rates of these events among patients and healthcare workers with similar risks. The data will be used to detect changes in the epidemiology of adverse events resulting from new and current medical therapies and changing risks. The NHSN currently consists of five components: Patient Safety, Healthcare Personnel Safety, Biovigilance, Long-Term Care Facility (LTCF), and Dialysis. The Outpatient Procedure Component is on track to be released in NHSN in 2017/2018. The development of this component has been previously delayed to obtain additional user feedback and support from outside partners.

Changes were made to six facility surveys and two new facility surveys were added. Based on user feedback and internal reviews of the annual facility surveys it was determined that questions and response options be amended, removed, or added to fit the evolving uses of the annual facility surveys. The surveys are being increasingly used to help intelligently interpret the other data elements reported into NHSN. Currently the surveys are used to appropriately risk adjust the numerator and denominator data entered into NHSN while also guiding decisions on future division priorities for prevention.

Further, three new forms were added to expand NHSN surveillance to pediatric ventilator-associated events, adult sepsis, and custom HAI event surveillance. An additional 14 forms were added to the Hemovigilance Component to streamline data collection/entry for adverse reaction events.

Additionally, minor revisions have been made to 22 forms within the package to clarify and/or update surveillance definitions. The previously approved NHSN package included 52 individual collection forms; the current revision request adds nineteen forms and removes one form for a total of 70 forms. The reporting burden will increase by 489,174 hours, for a total of 5,110,716 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Avg. burden per response (in hrs.)
Registered Nurse (Infection Preventionist)	57.100 NHSN Registration Form	2,000	1	5/60
Registered Nurse (Infection Preventionist)	57.101 Facility Contact Information	2,000	1	10/60

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Avg. burden per response (in hrs.)
Registered Nurse (Infection Preventionist)	57.103 Patient Safety Component—Annual Hospital Survey.	5,000	1	55/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.105 Group Contact Information	1,000 6,000	1 12	5/60 15/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.108 Primary Bloodstream Infection (BSI) 57.111 Pneumonia (PNEU)	6,000 6,000	44 72	30/60 30/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.112 Ventilator-Associated Event57.113 Pediatric Ventilator-Associated Event (PedVAE).	6,000 2,000	144 120	25/60 25/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.114 Urinary Tract Infection (UTI)	6,000 2,000	40 91	20/60 35/60
Staff RN	57.116 Denominators for Neonatal Intensive Care Unit (NICU).	6,000	9	3
Staff RN	57.117 Denominators for Specialty Care Area (SCA)/Oncology (ONC).	6,000	9	5
Staff RN Registered Nurse (Infection Preventionist)	57.118 Denominators for Intensive Care Unit (ICU)/Other locations (not NICU or SCA). 57.120 Surgical Site Infection (SSI)	6,000 6,000	60	5 35/60
Staff RN	57.120 Surgical Site Infection (331)	6,000	540	10/60
Laboratory Technician	57.123 Antimicrobial Use and Resistance (AUR)—Microbiology Data Electronic Upload Specification Tables.	6,000	12	5/60
Pharmacist	57.124 Antimicrobial Use and Resistance (AUR)—Pharmacy Data Electronic Upload Specification Tables.	6,000	12	5/60
Registered Nurse (Infection Preventionist)	57.125 Central Line Insertion Practices Adherence Monitoring.	1,000	100	25/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.126 MDRO or CDI Infection Form	6,000 6,000	72 24	30/60 15/60
Registered Nurse (Infection Preventionist)	toring. 57.128 Laboratory-identified MDRO or CDI Event.	6,000	240	20/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.129 Adult Sepsis	50 350	250 1	25/60 1.08
Registered Nurse (Infection Preventionist)	57.138 Laboratory-identified MDRO or CDI Event for LTCF.	350	12	15/60
Registered Nurse (Infection Preventionist)	57.139 MDRO and CDI Prevention Process Measures Monthly Monitoring for LTCF.	350	12	10/60
Registered Nurse (Infection Preventionist)	57.140 Urinary Tract Infection (UTI) for LTCF	350	14	30/60
Registered Nurse (Infection Preventionist)	57.141 Monthly Reporting Plan for LTCF	350	12	5/60
Registered Nurse (Infection Preventionist) Registered Nurse (Infection Preventionist)	57.142 Denominators for LTCF Locations 57.143 Prevention Process Measures Month- ly Monitoring for LTCF.	350 300	12 12	3.35 5/60
Registered Nurse (Infection Preventionist)	57.150 LTAC Annual Survey	400	1	55/60
Registered Nurse (Infection Preventionist)	57.151 Rehab Annual Survey	1,000	1	55/60
Occupational Health RN/Specialist	57.200 Healthcare Personnel Safety Component Annual Facility Survey.	50	1	8
Occupational Health RN/Specialist	57.203 Healthcare Personnel Safety Monthly Reporting Plan.	17,000	200	5/60
Occupational Health RN/Specialist Occupational Health RN/Specialist	57.204 Healthcare Worker Demographic Data. 57.205 Exposure to Blood/Body Fluids	50 50	200	20/60
Occupational Health RN/Specialist	57.206 Healthcare Worker Prophylaxis/Treatment.	50	30	15/60
Laboratory Technician Occupational Health RN/Specialist	57.207 Follow-Up Laboratory Testing 57.210 Healthcare Worker Prophylaxis/Treat- ment—Influenza.	50 50	50 50	15/60 10/60
Medical/Clinical Laboratory Technologist	57.300 Hemovigilance Module Annual Survey.	500	1	2
Medical/Clinical Laboratory Technologist	57.301 Hemovigilance Module Monthly Reporting Plan.	500	12	1/60
Medical/Clinical Laboratory Technologist	57.303 Hemovigilance Module Monthly Reporting Denominators.	500	12	1.17
Medical/Clinical Laboratory Technologist Medical/Clinical Laboratory Technologist	57.305 Hemovigilance Incident	500 200	10	10/60 35/60

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Avg. burden per response (in hrs.)
Medical/Clinical Laboratory Technologist	57.307 Hemovigilance Adverse Reaction— Acute Hemolytic Transfusion Reaction.	500	4	25/60
Medical/Clinical Laboratory Technologist	57.308 Hemovigilance Adverse Reaction— Allergic Transfusion Reaction.	500	4	25/60
Medical/Clinical Laboratory Technologist	57.309 Hemovigilance Adverse Reaction— Delayed Hemolytic Transfusion Reaction.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.310 Hemovigilance Adverse Reaction— Delayed Serologic Transfusion Reaction.	500	2	25/60
Medical/Clinical Laboratory Technologist	57.311 Hemovigilance Adverse Reaction— Febrile Non-hemolytic Transfusion Reaction.	500	4	25/60
Medical/Clinical Laboratory Technologist	57.312 Hemovigilance Adverse Reaction— Hypotensive Transfusion Reaction.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.313 Hemovigilance Adverse Reaction—Infection.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.314 Hemovigilance Adverse Reaction— Post Transfusion Purpura.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.315 Hemovigilance Adverse Reaction— Transfusion Associated Dyspnea.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.316 Hemovigilance Adverse Reaction— Transfusion Associated Graft vs. Host Disease.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.317 Hemovigilance Adverse Reaction— Transfusion Related Acute Lung Injury.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.318 Hemovigilance Adverse Reaction— Transfusion Associated Circulatory Overload.	500	2	25/60
Medical/Clinical Laboratory Technologist	57.319 Hemovigilance Adverse Reaction— Unknown Transfusion Reaction.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.320 Hemovigilance Adverse Reaction— Other Transfusion Reaction.	500	1	25/60
Medical/Clinical Laboratory Technologist	57.400 Patient Safety Component—Annual Facility Survey for Ambulatory Surgery Center (ASC).	5,000	1	5/60
Staff RN	57.401 Outpatient Procedure Component— Monthly Reporting Plan.	5,000	12	15/60
Staff RN	57.402 Outpatient Procedure Component Event.	5,000	25	40/60
Staff RN	57.403 Outpatient Procedure Component— Monthly Denominators and Summary.	5,000	12	40/60
Staff RN	57.500 Outpatient Dialysis Center Practices Survey.	6,500	1	2.0
Registered Nurse (Infection Preventionist)	57.501 Dialysis Monthly Reporting Plan	6,500	12	5/60
Staff RN	57.502 Dialysis Event	6,500	60	25/60
Staff RN	57.503 Denominator for Outpatient Dialysis	6,500	12	10/60
Staff RN	57.504 Prevention Process Measures Monthly Monitoring for Dialysis.	1,500	12	1.25
Staff RN	57.505 Dialysis Patient Influenza Vaccination	325	75	10/60
Staff RN	57.506 Dialysis Patient Influenza Vaccination Denominator.	325	5	10/60
Staff RN	57.507 Home Dialysis Center Practices Sur-	600	1	25/60

Jeffrey M. Zirger,

Health Scientist, Acting Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016-18710 Filed 8-5-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-16-0010]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the